Jurgimeda, MB - financials and debts

Company age: 3 y. 1 mo.

Update

Jurgimeda - Company finances

EUR
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 70,181 71,947
Profit before tax 17,167 12,057
Net profit 16,309 11,334
Equity 22,401 33,735
Liabilities 6,004 5,869
Non-current assets 0 0
Current assets 28,405 39,539
Total assets 28,405 39,539
Taxes paid
STI taxes - 858
Financial indicators
Revenue change y/y - +2.5%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 57.4% 28.7%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 72.8% 33.6%
Profit margin Net profit margin. Shows the overall profitability of the company. 23.2% 15.8%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 24.5% 16.8%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 0.3 0.2
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - -

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Jurgimeda - Social security debts

From To Debt, €
2024-09-03 2024-10-31 193.50
2024-08-01 2024-09-02 129.00
2024-07-02 2024-07-31 64.50
2024-06-03 2024-06-30 193.50
2024-05-02 2024-06-02 129.00
2024-04-03 2024-05-01 64.50
2024-03-01 2024-03-31 129.00
2024-02-01 2024-02-29 64.50
2024-01-03 2024-01-31 175.89
2023-12-01 2024-01-02 117.26
2023-11-03 2023-11-30 58.63

Jurgimeda - VMI tax arrears

From To Overdue, €
2025-07-01 2025-07-31 2.53
2025-06-28 2025-06-28 858.0

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Jurgimeda, MB (company code 306391256) is a small partnership active in traditional, complementary and alternative medicine activities. In the latest financial year, 2025, the company generated revenue of €71.9K, up 2.5% year on year from €70.2K in 2024. Net profit for 2025 was €11.3K, compared with €16.3K in 2024, while profit before tax declined from €17.2K to €12.1K. As a result, the net profit margin decreased from 23.2% in 2024 to 15.8% in 2025, showing that profitability softened despite modest sales growth. Over the two-year period, the business increased its balance sheet size: total assets rose from €28.4K to €39.5K, and equity increased from €22.4K to €33.7K. Liabilities remained low and stable at €5.9K in 2025, compared with €6.0K a year earlier. For 2025, the company posted a return on equity of 33.6%, return on assets of 28.7%, a debt-to-equity ratio of 0.17, and asset turnover of 1.82x, indicating efficient use of its asset base.